Cancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity provides the reader with a basic understanding on how the ovary is adversely impacted by cancer treatment, an essential foundational knowledge for this rapidly-developing field. The book describes both the clinical and laboratory approaches to discovering the potentially adverse effects of cancer treatment on the ovary, also laying out possible preventative approaches and future directions for the field. Clinicians working in the field of reproductive biology and oncology will find an essential reference that provides the necessary tools to assess the reproductive toxicological effects of cancer treatments.

The Editor of this publication is Dr Elise Olsen, Director of the Duke University Cutaneous Lymphoma Research and Treatment Center and professor of Dermatology and Oncology. In 2014, cutaneous lymphoma (CL) is considered a chronic, non-life threatening disease since the majority of patients are diagnosed at early stage, though progression to later stages does result in death from the disease. This issue covers T-cell and B-cell lymphomas, with content emphasis on Mycoides fungoides and Sezary syndrome, the two most common clinically encountered subtypes of CL. Pharmaceutical treatment of the disease is a part of each article and the issue uses the following Treatment outline: Mechanisms of action - Pharmacokinetics - Typical dosing - Response to therapy - Adverse effects - and Pearls to help management using the agent under discussion. Beyond Dermatologists, specialists who would find the information useful are Cancer specialists, Hematologists/Oncologists, Physician Assistants, Nurse Practitioners, and Pharmacists. Some of the topics, written by the word's top experts in this disease, are: Overview of primary cutaneous lymphomas and the applicable staging and classification; Pathologic diagnosis of cutaneous lymphomas; in the section on Mycosis Fungoides and Sezary Syndrome, the clinician and researcher will find such topics as Skin directed medications; Phototherapy; Systemic retinoids; Interferons; HDAC inhibiotrs, Methotrexate and praletexate, along with other chemotherapeutic agents. Also, Bone marrow transplant; Diagnosis and management of CD30+ Lymphoproliferative disorders; and Diagnosis and management of primary cutaneous B cell lymphomas.

This issue of Hematology/Oncology Clinics of North America is devoted to Congenital and Acquired Disorders of Macrophages and Histiocytes. Guest Editors Nancy Berliner, MD and Barrett Rollins, MD have assembled a group of expert authors to review the following topics: Nosology of Langerhans Cell Histiocytosis (LCH); Cell of Origin of LCH; Genomic Changes in LCH; Clinical Treatment of LCH; Neurodegeneration in LCH; Pathogenesis of Hemophagocytic Lymphohistiocytosis (HLH); Familial HLH; HLH in Adults; Macrophage Activation Syndrome; and Stem Cell Transplant for HLH.

It has been recognized for almost 200 years that certain families seem to inherit cancer. It is only in the past decade, however, that molecular genetics and epidemiology have combined to define the role of inheritance in cancer more clearly, and to identify some of the genes involved. The causative genes can be tracked through cancer-prone families via genetic linkage and positional cloning. Several of the genes discovered have subsequently been proved to play critical roles in normal growth and development. There are also implications for the families themselves in terms of genetic testing with its attendant dilemmas, if it is not clear that useful action will result. The chapters in this work illustrate what has already been achieved and take a critical look at the future directions of this research and its potential clinical applications.

This invaluable resource discusses insights ranging from basic biological mechanisms of various types of stem cells through the potential applications in the treatment of human diseases, including cancer and genetic disorders. These discoveries are placed within the structural context of tissue and developmental biology in sections dealing with recent advances in understanding different types of stem cell biology and their potential applications in tissue repair and regeneration and in the treatment different types of human cancer and genetic diseases or disorders. Stem Cells for Cancer and Genetic Disease Treatment and the other books in the Stem Cells in Clinical Applicationsseries will be invaluable to scientists, researchers, advanced students and clinicians working in stem cells, regenerative medicine or tissue engineering as well as cancer or genetics research.

This book shares the latest research and practice-oriented findings in medical sciences with a wide audience. It addresses a range of contemporary issues, often unresolved or contentious, across various medical fields, including advances in the management of hemorrhagic brain stroke. It also discusses metastatic renal cell carcinoma - a global scourge with an extremely poor long-term survival prognosis, the course and sequelae of renal cell carcinoma, as well as advances in targeted molecular therapy with sunitinib, a receptor tyrosine kinase inhibitor. Further, it examines the molecular targeting of proliferative signaling of the epidermal growth factor receptor in the first-line treatment of patients with metastatic non-small-cell lung cancer. Other articles cover clearance of toxins in hemodialyzed patients; the search for diagnostic and therapeutic markers in the connective tissue disease scleroderma; obesity linked to inappropriate dietary habit; clinical problems related to the diagnosis of sensitization to fungi and its role in asthma; and reasons for the perilous trend of avoiding basic vaccinations in children. Lastly, the book explores the rapid developments in e-health technologies that increase access to health services, particularly for the elderly. The book is intended for clinical specialists, researchers, and all allied health professionals from various fields.

This volume provides insight into the pivotal roles of stem cells, exosomes and other microvesicles in biofunction and molecular mechanisms and their therapeutic potential in translational nanomedicine. It further highlights evidence from recent studies as to how stem cell derived exosomes and microRNAs may restore and maintain tissue homeostasis, enable cells to recover critical cellular functions and begin repair regeneration. These early studies in animal models of aging also show evidence of improved immune, cardiovascular and cognitive functions as well as improved health span and life span. The use of exosomes from body fluids to define specific biomarkers for various tumors may also clear the path to patient-targeted treatments by developing exosome-derived microRNA based cancer therapeutics. It is essential reading for graduate students, research fellow and biomedical researchers in academia or the pharmaceutical or biotech industries.

This issue of Surgical Oncology Clinics of North America, edited by Thomas Weber, MD, is devoted to Genetic Testing in Surgical Oncology. Articles in this issue include: The Critical Importance of Timely Genetic Testing; Securing and Documenting Cancer Family History in the Age of the Electronic Medical Record; Cancer Family Registries: Vital Tools for Patient Management and Cancer Genetics Translational Research; The Genetics of Breast Cancer; The Genetics of Colorectal Cancer: HNPCC, FAP MYH, and Hamartomatous Syndromes Including Peutz-Jeghers and Jevenile Polyposis; Hereditary Gastric Cancer Syndromes; Hereditary Pancreatic Cancer Syndromes; Hereditary Melanoma: Genetics and Multidisciplinary Management; Multiple Endocrine Neoplasia: Genetics and Clinical Management; Sequence Variants of Uncertain Significance (VUS): What To Do When Genetic Testing Results Are Not Definitive; Confidentiality and the Risk of Genetic Discrimination: What Surgeons Need to Know; and A Certified Genetic Counselor: A Crucial Clinical Resource in the Management of Patients with Suspected Hereditary Solid Tumor Syndromes.

Cancers of the larynx, while survival outcomes increase, result in massive treatment damage from radiation and surgery. Patients often lose ability to speak and to eat. Preserving the larynx is a fine balance of cancer eradication, life extension, and quality of life. This issueof Otolaryngologic Clinics led by Dr Babak Sadoughi should be of interest to Otolaryngologists, Oncologists, Radiologists, and Speech Therapists. The issue approach reaches all the most important aspects of diagnosing and treating the patient with laryngeal cancer with a focus on preserving the voice in early laryngeal cancer and preserving and restoring function in advanced laryngeal cancer. Topics include: Functional Anatomy and Oncological Barriers of the Larynx; Evaluation of the Dysphonic Patient; Role of Advanced Laryngeal Imaging in Glottic Cancer; Laryngeal Function after Radiation Therapy; Management of Dysphonia after Radiation Therapy; Contemporary Surgical Management of Early Glottic Cancer; Voice Prognosis after Transoral Laser Microsurgery of the Larynx; Voice Rehabilitation after Transoral Laser Microsurgery of the Larynx; Quality of Life after Conservation Surgery for Laryngeal Cancer; Salvage Conservation Surgery of the Larynx; Airway Preservation in Ablative Laryngeal Surgery; Voice Restoration after Total Laryngectomy. A special article for Residents, written by a Resident, emphasizes essential "take home messages" for laryngeal function preservation diagnosis and treatment.

Drs. Robert J. Lewandowski and Matthew S. Davenport have assembled an expert panel of authors on the topic of Interventional Radiology. Articles will include: Abdominal Biopsy: Technical and Clinical Considerations; Intra-arterial Therapies for Liver Masses; Liver Ablation: Best Practice; Renal Intervention; Imaging (Findings) after Intervention; Assessing Imaging Response to Therapy; Liver Masses: Imaging Evaluation in Non-cirrhotics; Imaging in Cirrhotics: Current Evidence; Renal Masses: Imaging Evaluation; Adrenal Imaging/Intervention; The Pancreas; and more!

Cancer Screening and Genetics is reviewed extensively in this important Surgical Clinics of North America issue. Articles include: Cancer Genetics and Implications for Clinical Management; Epigenetics and Cancer; Screening and Early Detection of Cancer: Successes and Failures; Screening for Lung Cancer; Screening for Breast Cancer; Viral Hepatitis and Hepatocellular Cancer: How Should Patients Be Screened?; Screening for Pancreatic Cancer: Where Do We Stand?; Hereditary Colorectal Cancer: Genetics and Screening; Personalized Approach to Gastrointestinal Cancers; Screening for Colorectal Cancer; Screening for Prostate Cancer: Why the Controversy?; Gastric Cancer: East versus West-Is screening and early detection the difference?; and more!

This issue of Hematology/Oncology Clinics of North America is devoted to Pancreatic Cancer. Guest Editor Brian Wolpin, MD has assembled a group of expert authors to review the following topics: Biology and genetics of pancreatic adenocarcinoma; Mouse models of pancreatic adenocarcinoma; Epidemiology and inherited predisposition for sporadic pancreatic adenocarcinoma; Familial pancreatic adenocarcinoma; Imaging and endoscopic approaches to pancreatic cancer; Diagnosis and management of pancreatic cystic neoplasms; Surgical management of pancreatic cancer; Peri-operative therapy for surgically resectable pancreatic adenocarcinoma; Diagnosis and management of borderline resectable pancreatic adenocarcinoma; Treatment approaches to locally advanced pancreatic adenocarcinoma; Therapeutic approaches for metastatic pancreatic adenocarcinoma; Supportive and end-of-life care for patients with pancreatic adenocarcinoma; and Novel therapeutics for pancreatic adenocarcinoma.

This volume presents state of the art of methods that can be useful for both basic and translational researchers to conduct chemoprevention preclinical studies. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Cancer Chemoprevention: Methods and Protocols aims to ensure successful results in the further study of this vital field.

This book sheds new light on "inducible" lymphoid organs (ILOs): antigen presentation sites that are generated de novo in peripheral tissues under various pathogenic conditions. Accomplished immunologists demonstrate that the physiological role of these ILOs is completely different from that of central lymphoid organs, i.e., the lymph nodes or spleen. In addition to the central organs, the ILOs are considered essential structures for the efficient elicitation of adaptive immune responses in lesions. The respective chapters highlight examples from multiple sites, e.g. the skin, lung, intestinal tract, genital tract, the synovial membrane of the joints and artificial lymph nodes. Accordingly, readers will learn that ILO structure and function can vary substantially, depending on the context. Presenting the results of the latest immunological research, the book offers a fascinating and insightful read for both scientists and clinicians in the areas of infectious and immune-associated diseases.

Revealing essential roles of the tumor microenvironment components in cancer progression, this book provides a comprehensive overview of the latest research on the tumor microenvironment in several organs, including brain, neck, tongue, larynges, esophagus, carotid body, breast, prostate, ovary, endometrium, liver, pancreas, bladder, penis, seminal vesicle, retina, and pituitary, pineal and sweat glands, and more. Taken alongside its companion volumes, Tumor Microenvironments in Organs: From the Brain to the Skin - Part B updates us on what we know about the different aspects of the tumor microenvironments in distinct organs as well as future directions. This book is essential reading for advanced cell biology and cancer biology students as well as researchers seeking an update on research in the tumor microenvironment.

This volume is essential for geneticists, molecular biologists, biochemists, and medical doctors interested in the use of mouse models in cancer research. Recent genome studies, together with refined genetic engineering techniques, have greatly increased the value of using mice for research on cancer and other human disorders. The chapters of this book will support scientists in choosing the most suitable mouse models for their research questions. The book provides detailed methodological information for genetic or chemical induction of different types of cancer, histomorphometric cancer analysis, and in vivo imaging, as well as protocols to investigate oncogene addiction, immune surveillance, and hallmarks of cancer such as angiogenesis or metastasis. Four review-like articles provide background information on mouse technologies and histopathologic differences between mouse and human cancers. The mouse models described in individual chapters will fuel the understanding of cancer initiation, immune system roles, tumor angiogenesis, invasion, metastasis, and the relevance of molecular diversity observed among human cancers. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and resourceful, Mouse Models of Cancers: Methods and Protocols, is a valuable laboratory resource for all researchers, from the graduate level upwards, who study cancer and new possibilities for its treatment.

This book highlights information derived primarily from clinical samples, with particular reference to theoretical and scientific aspects of the human immune system. This text will focus on topics that range from host-pathogen interactions in infectious disease to host immune response in cancer, allergic diseases, neuroinflammatory diseases, and autoimmune disorders. The reader will also have a well-rounded understanding of the behavior of the immune system with particular emphasis on the role of immunoproteomics in immunotherapy, neuroprotective immunity for neurodegenerative and neuroinfectious disease, leukemia-associated dendritic cell induction of adaptive immunity dysregulation, and the role of immune checkpoint inhibitors in cancer, infection, as well as neuroinflammation. Taken together, the contents of this book are intended for both clinicians and researchers in academia and industry.

The Integrated Control of Cell Proliferation and Cell Viability; G.I. Evan, et al. Control of Invasive Cell Growth by the MET Family Oncogenes; F. Galimi, P.M. Comoglio. Src Family Kinases and the Cell Cycle; S.A. Courtneidge. p16 Family Inhibitors of Cyclin-Dependent Kinases; Y. Li, et al. p53-Mediated Apoptosis: Regulatory and Mechanistic Aspects; Y. Haupt, et al. The Molecular Genetics of Wilms Tumor; J. Pelletier, et al. HTLV-1 Tax: A Paradigm for How a Single Auxiliary Factor Can Regulate the Expression of Viral and Cellular Genes; G. Perini, M.R. Green. CREM: Transcriptional Pacemaker of the cAMP Response; J.S. Lee, et al. MADS-domain transcription Factor and Their Accessory Proteins (TCFs): Nuclear Targets for Growth Control Signals; M.A. Cahill, et al. Retinoblastoma Protein, Gene Expression, and Cell Cycle Control; J.C. Azizkhan, et al. Cyclin A-kinase Binding to and Regulation of the Function of a Growth-Promoting Transcription Factor; W. Krek, et al. Homeostatic Mechanisms Governing the Go hase as Defined by the Gas Genes; C. Schneider, et al. The TEL Gene and Human Leukemias; T.R. Golub, et al. Characterization of the TCLI Gene and Its Involvement in T-Cell Malignancies; L. Virgilio, et al. 3 Additional Articles. Index.

This issue of Hematology/Oncology Clinics, guest edited by Dr. F. Stephen Hodi, is devoted to Melanoma. Articles in this issue include: The current state of Melanoma; Understanding the Biology of Melanoma Development and Therapeutic Implications; Surgical Management of Melanoma; Targeted Therapies for Cutaneous Melanoma; Treatments for Non-cutaneous Melanoma; Resistant Mechanisms and Therapeutic Implications; The Role of the Immune System in Melanoma Development and Treatment; Vaccines and Melanoma; IL-2, Interferon, and Cytokines; Immune Checkpoint Blockade; Adjuvant Treatments, Chance for Cure in Melanoma; and Combinatorial Approach to Treatment of Melanoma.

The Guest Editors have assembled top key opinion leaders to provide current reviews on the multidisciplinary approach to the management of high-grade bladder cancer. Articles are devoted to fluorescence cystoscopy, confocal laser endomicroscopy, narrow band imaging; Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer; Trimodality therapy in bladder cancer; the data and the reality of perioperative chemotherapy in muscle invasive bladder cancer; radical transurethral resection alone, robotic or partial cystectomy or extended lymphadenectomy: Neoadjuvant paradigm for drug development in muscle invasive bladder cancer; Novel biomarkers to predict response and prognosis in localized bladder cancer; Immunotherapy in Advanced/Metastatic Urothelial Cancer ; and Adjuvant Chemotherapy in High Grade Upper Tract Urothelial Cancer.

The Editors for this 2-part issue of Otolaryngologic Clinics, Dr George Wanna and Dr Matthew Luke Carlson, envisioned a publication that reviews the evaluation and management of common ear and lateral skull base tumors. Intended audience includes Otologists, Neurotologists, General otolaryngologists and Neurosurgeons alike. The development of management of lateral skull base tumors has been rapid, in the past 40 years there has been a tremendous shift toward conservative therapy for benign lesions. Focused chapters review specific pathologies plus a chapter focused on stereotactic radiotherapy. Topics written by reputed leaders in the field of Otology and skull base tumors include: Imaging of temporal bone lesions; Squamous cell carcinoma of the temporal bone; Glomus tympanicum; Adenomatous tumors of the middle ear; Intralabyrinthine schwannomas; Vestibular schwannoma; Neurofibromatosis2 (including ABI and CI); Non-schwannoma tumors of the CPA; Glomus jugulare; Endolymphatic sac tumors; Non-paraganglioma jugular foramen tumors; Primary tumors of the facial nerve; Cholesterol granuloma and other petrous apex lesions; Stereotactic radiosurgery for tumors of the lateral skull base; Pediatric temporal bone malignancy; and Historical perspective on evolution in management of lateral skull base tumors.

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, and more. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Originally published by Bentham and now distributed by Elsevier, Anti-Angiogenesis Drug Discovery and Development, Volume 2 is an compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. These reader-friendly chapters cover topics of great scientific importance, many of which are considered significant medical breakthroughs, making this book excellent reading both for the novice as well as for expert medicinal chemists and clinicians.

Today's consumers are looking for food products with health-promoting roles in addition to nutritional benefits. With current research showing that nutraceuticals and functional foods rich in specific bioactives may have chemopreventative effects, these products are increasingly popular. However, while much in the literature supports the health-promoting features of these foods, few texts focus on their bioactive agents and their mode of action in cancer signaling. Nutraceuticals and Cancer Signalling: Clinical Aspects and Mode of Action explains the link between nutraceuticals and cancer in terms of clinical trials and modes of action. This book gives an overview of common cancers and their mechanisms, and the most common functional foods and their bioactive components. Individual chapters focus on specific functional foods--including tomatoes, garlic, honey, tea, yoghurt, and many more--their prominent bioactive compounds, and their mode of action in cancer signaling and chemoprevention. Recent findings on cancer-prevention roles of different vitamins and minerals are also discussed. For food scientists, nutritionists, and pharmaceutical experts looking to understand how functional foods can play a role in fighting cancer, this text serves as a one-stop reference.

This issue of Recent Results in Cancer Research presents a comprehensive review of current understanding of chromosomal instability in cancer and of strategies to use this information for better treatment of patients with cancer. Cancer is a disease of the chromosomes, and chromosomal instability in cancer disrupts gene function by either inactivating tumor suppressor genes or activating growth-promoting oncogenes. The chromosomal basis for these aberrations is either translocations, which change the integrity of genes, or abnormal numbers of chromosomes, a condition referred to as aneuploidy, which results in abnormal gene expression levels. Such structural or numerical chromosomal aberrations are specific for distinct tumor entities. The degree of chromosomal instability and the degree of intratumor heterogeneity have profound consequences for disease outcome and for therapeutic stratification.